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Abstract
Background: Germ line mutations in BRCA1 and BRCA2 (BRCA1/2) and other susceptibility genes have been
identified as genetic causes of hereditary breast and ovarian cancer (HBOC). To identify the disease-causing
mutations in a cohort of 120 Brazilian women fulfilling criteria for HBOC, we carried out a comprehensive
screening of BRCA1/2, TP53 R337H, CHEK2 1100delC, followed by an analysis of copy number variations in 14
additional breast cancer susceptibility genes (PTEN, ATM, NBN, RAD50, RAD51, BRIP1, PALB2, MLH1, MSH2, MSH6,
TP53, CDKN2A, CDH1 and CTNNB1).
Methods: Capillary sequencing and multiplex ligation-dependent probe amplification (MLPA) were used for
detecting point mutations and copy number variations (CNVs), respectively, for the BRCA1 and BRCA2 genes;
capillary sequencing was used for point mutation for both variants TP53 R337H and CHEK2 1100delC, and finally
array comparative genomic hybridization (array-CGH) was used for identifying CNVs in the 14 additional genes.
Results: The positive detection rate in our series was 26%. BRCA1 pathogenic mutations were found in 20 cases,
including two cases with CNVs, whereas BRCA2 mutations were found in 7 cases. We also found three patients
with the TP53 R337H mutation and one patient with the CHEK2 1100delC mutation. Seven (25%) pathogenic
mutations in BRCA1/2 were firstly described, including a splice-site BRCA1 mutation for which pathogenicity was
confirmed by the presence of an aberrant transcript showing the loss of the last 62 bp of exon 7. Microdeletions of
exon 4 in ATM and exon 2 in PTEN were identified in BRCA2-mutated and BRCA1/2-negative patients, respectively.
Conclusions: In summary, our results showed a high frequency of BRCA1/2 mutations and a higher prevalence of
BRCA1 (64.5%) gene. Moreover, the detection of the TP53 R337H variant in our series and the fact that this variant
has a founder effect in our population prompted us to suggest that all female breast cancer patients with clinical
criteria for HBOC and negative for BRCA1/2 genes should be tested for the TP53 R337H variant. Furthermore, the
presence of genomic structural rearrangement resulting in CNVs in other genes that predispose breast cancer in
conjunction with BRCA2 point mutations demonstrated a highly complex genetic etiology in Brazilian breast
cancer families.
Keywords: Breast cancer, Mutation, BRCA1, BRCA2, HBOC, CHEK 1100delC, TP53 R337H
* Correspondence: dirce.carraro@cipe.accamargo.org.br
†Equal contributors
1Laboratory of Genomics and Molecular Biology, CIPE - A. C. Camargo Cancer
Center, São Paulo, Brazil
3National Institute of Science and Technology in Oncogenomics (INCITO),
São Paulo, Brazil
Full list of author information is available at the end of the article
© 2014 Silva et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Silva et al. BMC Medical Genetics 2014, 15:55
http://www.biomedcentral.com/1471-2350/15/55
Background
Hereditary breast and ovarian cancer (HBOC) accounts
for 5-10% of all breast cancer (BC) cases and is inherited
in an autosomal dominant fashion. Nearly 30% of HBOC
patients harbor germ line point mutations or genomic
structural rearrangements that result in copy number
variations (CNVs) in BRCA1/2 genes, with a lifetime risk
of 45-70% for BC and 20-40% for ovarian cancer [1].
Mutations in these genes also confer a slightly increased
risk of other types of cancer, such as pancreatic, primary
peritoneal, prostate, male breast and fallopian tube
cancer [2].
Germ line BRCA1 (MIM# 113705) and BRCA2 (MIM#
600185) mutations are also frequently found in isolated
cases of bilateral and/or early-onset BC [3]. The frequency
of these mutations is variable because a higher frequency
of BRCA1 mutations has been described in the United
States [4], whereas a clear prevalence of BRCA2 mutations
has been reported in Icelandic BC families [5]. Conversely,
similar mutation frequency in both genes has been
described in French Canadian and British families [6,7].
Inherited mutations in other genes also influence the
risk of BC. The CHEK2 1100delC has been associated
with higher BC risks [8], conferring a two-fold increase
in BC risk for women and a ten-fold increase for men
[8-10]. Recent studies in cancer-prone families in south-
east Brazil have identified a founder germ line TP53 muta-
tion (p.R337H) at a higher prevalence (1:3,000) than the
others germ line TP53 mutations [11]. A variety of cancer
types have been found in TP53 p.R337H-carrying families,
such as soft tissue sarcomas, brain tumors, adrenocortical
carcinomas and breast cancers [11].
Screening for mutations in the tumor suppressor genes
BRCA1 and BRCA2 is of great significance for breast
and ovarian cancer prevention and early detection. When
a mutation is identified, the cancer risk can be reduced via
prophylactic mastectomy; patients can also seek effective
screening strategies to detect breast cancer earlier [12].
Moreover, whether a mutation is detected, the genetic
testing can be extended to relatives who can enter in spe-
cific screening programs for carriers or follow the strategy
for the general population (non-carriers). More recently,
emerging therapies, such as PARP inhibitors in combin-
ation with conventional treatment, have been shown
to be more effective for BRCA1 and BRCA2 mutation
carriers [13].
The complex genetic basis of hereditary breast cancer
prompted us to perform a comprehensive genetic in-
vestigation of 120 Brazilian patients fulfilling clinical
criteria for HBOC. We screened the BRCA1/2 genes
for point mutations and CNVs. We also evaluated the
presence of the CHEK2 1100delC and TP53 R337H
variants via sequencing and used array comparative
genomic hybridization (array-CGH) to investigate CNVs
in 14 additional breast cancer-predisposing genes: PTEN,
ATM, NBN, RAD50, RAD51, BRIP1, PALB2, MLH1,
MSH2, MSH6,TP53, CDKN2A, CDH1 and CTNNB1.
Methods
Patients
One hundred twenty unrelated breast cancer patients ful-
filling criteria for hereditary breast and ovarian cancer
(HBOC) were recruited from 2007 to 2010 for this study.
The inclusion criteria were: 1) Breast cancer diagnosed ≤
45 years of age (no family history); 2) Breast cancer diag-
nosed ≤ 45 years of age with 1 or more close blood relative
with breast/ovarian/fallopian tube/primary peritoneal can-
cer at any age; 3) Breast cancer diagnosed <45 ≤ 50 years
of age with 1 or more blood relative with breast/ovarian/
fallopian tube/primary peritoneal cancer ≤ 50 years of age;
4) Breast cancer diagnosed >50 of age with 1 or more
blood relative with breast/ovarian/fallopian tube/primary
peritoneal cancer at any age; 5) Two primary BC when the
first occurrence was prior to age 50; 6) Breast cancer
with a history of ovarian/ fallopian tube/primary peri-
toneal cancer at any age; 7) For an individual with an
ethnicity that is associated with a higher mutation
frequency (e.g., Ashkenazi Jewish); 8) Personal history
of ovarian/fallopian tube/primary peritoneal cancer; 9)
Personal history of male breast cancer. All enrolled
individuals received genetic counseling and signed an
informed consent. This study was performed in compli-
ance with the Helsinki Declaration and was approved by
the ethics committee of the A C Camargo Cancer Center
(approval number: 870/06-B). The complete clinical and
molecular information of the patients is given in the
Additional file 1.
Point mutation screening
DNA from peripheral blood was purified using the
Puregene Genomic DNA Isolation kit (Quiagen, Hilden,
Germany) according to manufacturer’s instructions. The
entire coding sequence and exon-intron boundaries of the
BRCA1 (U14680 or NM_007294.3) and BRCA2 (U43746
or NM_000059.1) genes were evaluated. The CHEK2 gene
(NM_007194.3) and the TP53 gene (NM_000546.5) were
screened solely for the c.1100delC and p.R337H muta-
tions, respectively. All PCR products were sequenced in
both forward and reverse directions on an ABI Prism
3130xl genetic analyzer (Life Technologies, Foster City,
USA). Mutations were recorded and referenced with
respect to the cDNA sequence using the nomenclature
proposed by the BIC database [14]. PCR conditions and
primer sequences are available upon request.
Investigation of BRCA1/2 CNVs by MLPA
Patients negative for BRCA1/2 mutations were investigated
for CNVs in these genes. Exonic deletions and duplications
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affecting BRCA1 and BRCA2 genes were investigated on
genomic DNA using the multiplex ligation-dependent
probe amplification (MLPA) commercial kits P087-B1 and
P045-B3 (MRC-Holland, Amsterdam, The Netherlands)
according to the manufacturer’s recommendations.
Classification of variants
The BIC database was searched for all BRCA1 and BRCA2
alterations [14]. Unreported mutations that generated a
premature stop codon (nonsense and frameshift) were
classified as pathogenic. Missense alterations classified as
class 3 in the IARC_LOVD database [15] or unknown in
the BIC database were considered to be variants of uncer-
tain significance (VUSs). Variants classified as class 1 and
2 using the IARC_LOVD were considered to be wild type.
In cases of inconsistency between the databases, the
classification from IARC-LOVD prevailed. Additionally,
the VUSs were characterized using three in silico protein
prediction algorithms: SIFT [16], POLYPHEN-2 [17] and
Align-GVGD [18].
Transcript analysis
For transcriptional analysis of the novel splice site variant,
frozen tumor tissues were obtained from the carrier and
from a sporadic breast tumor that was negative for muta-
tions in the BRCA1 gene, which was used as a control
sample. RNA samples were purified using the Precellys
24® equipment (Carlsbad, California, USA), followed by
total RNA extraction using an RNeasy Mini kit (Qiagen,
Venlo, The Netherlands). The first strand cDNA was
synthesized from 2 μg of total RNA using a random hex-
amer primer with the Superscript first strand system for
RT-PCR (Life Technologies, Foster City, USA). RT-PCR
fragments of the index patient and the control sample
were both obtained according to standard PCR protocols
using primers adjacent to the exon involved in the splice
site mutation. All RT-PCR products were inserted into the
T/A plasmid vector pTZ57R/T using the InsT/Aclone
PCR Product Cloning Kit (Thermo Fisher Scientific,
USA), and the ligated plasmid was used for transformation
in DH10B E. coli cells via electroporation (2.5 KV, 25 μ
FD, 200 OHMS), followed by single-colony sequencing on
the ABI 3130xl sequencer using M13 primers.
Screening of copy number alterations via array
comparative genomic hybridization (array-CGH)
Genomic CNVs affecting 14 cancer susceptibility genes
(PTEN, TP53, ATM, NBN, RAD50, BRIP1, PALB2,
RAD51, MLH1, MSH2, MSH6, CDKN2A, CDH1 and
CTNNB1) were investigated in oligo-based array-CGH
data obtained from a previous study [19]. All hybri-
dizations were gender-matched and processed in reverse
labeling duplicates; experiments were carried out using
the 180 K whole genome platform (design 22060, Agilent
Technologies, Santa Clara, CA, USA). The Agilent
Genomic Workbench software was used for the detection
of CNVs (deletion and duplications) with the aberration
detection method 2 (ADM-2) and a threshold of 6.7.
The duplication or deletion of genomic segments were
declared when one probe exhibited a log2 ratio of Cy3/
Cy5 > 0.70 or < −0.70, respectively. A careful visual inspec-
tion was performed to filter out poor quality hybridiza-
tions and noisy data. Additionally, alterations located
more than 3 kb upstream or downstream of the coding
exons were excluded. The Database of Genomic Variants
(DGV-HG19, http://projects.tcag.ca/variation/) was used
to exclude common variants detected in the general popu-
lation. Only alterations detected in both experiments of
the same patient were considered.
Gene dosage qPCR
To validate the genomic DNA CNVs, we used the quan-
titative duplex PCR method previously described [20].
GAPDH was used as a reference gene. For array-CGH
probes located in introns, PCR primers were designed to
encompass the closest exon.
Results
Screening of BRCA1/2: point mutations and copy number
variations; CHEK2 1100delC and TP53 R337H
The mean age of diagnosis of the first primary tumor in
all 120 patients was 43 years-old (yo), with a range from
22 to 88. Thirty-one out of 120 patients (26%) were found
to harbor pathogenic mutations, including 20 for BRCA1
(64.5%), seven for BRCA2 (22.5%), three for TP53 R337H
(10%) and one for CHEK2 1100delC (3%). In the BRCA1
gene, 20 patients presented 18 different mutations, of
which 16 were point mutations (89%) (Six nonsense, six
frameshift, two splice site and two missense) and two were
CNVs, one deletion encompassing exons 16 and 17 and a
rare case of exon 24 amplification detected within BRCA1
(11%) (Table 1 and Additional file 2). The Ashkenazi Jewish
mutation c.5382insC was the most recurrent and was
found in three cases. The seven BRCA2 carriers presented
six distinct mutations, of which three were nonsense and
three were frameshift. The nonsense variant c.9709A > T
was found in two cases. No CNVs were detected in
BRCA2. Moreover, seven out of 28 (25%) BRCA1/2-car-
riers were found to harbor novel pathogenic mutations,
five in BRCA1 and two in BRCA2.
Interestingly, patient MO-15 was found to harbor a
germ line splice site mutation (c.560 + 2 T > A) in intron 7
of the BRCA1 gene (Figure 1A). RT-PCR products encom-
passing part of exon 6 to exon 8 revealed the presence of
a 186-bp fragment in addition to the expected fragment of
258 bp (Figure 1B). Sequencing of the 186-bp fragment
disclosed a frameshift deletion of the last 62 bp of exon 7
due to the activation of a novel cryptic splice site within
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exon 7 (Figure 1C). Figure 1D shows the schematic
representation of the premature stop codon created in
the mRNA after the deletion of 62 bp of exon 7 (r.[=,
499_560del); p.Ser127Thrfs*11) caused by the germ line
splice site mutation c.560 + 2 T > A. The predicted protein
from the aberrant mRNA apparently created an isoform
of 137aa (Figure 1E).
Nineteen out of 120 HBOC patients (16%) harbored
VUSs according to our criteria (based on BIC and/or
IARC-LOVD databases - see the Methods section). Among
the VUS carriers, 17 variants were distinct, and two of
them were described for the first time (Table 2). The VUS
evaluation using the three protein prediction algorithms
(PolyPhen, SIFT and GVGD-Align) showed that six were
classified as likely pathogenic by at least one algorithm
(three in one algorithm, two in two algorithms and one in
all three algorithms). The schematic representation of all
VUSs in the BRCA1 and BRCA2 genes and their functional
domains on the protein are shown in Figure 2.
Mutation frequency by inclusion criteria
Overall, the mutation detection rate was 26%; however,
when selecting according to age of cancer onset, young
women (≤35 yo) had the highest rate at 35% (Figure 3).
Regarding specific HBOC criteria fulfilled by each family,
the majority of mutation carriers (45%) met criterion 2
(Breast cancer diagnosed ≤ 45 yo and familial history
positive for BC). Four out of five patients fulfilling the
Table 1 Clinical and molecular description of the BRCA1, BRCA2, CHEK2 1100delC and TP53 R337H mutation carriers
Proband Age of onset Tumor Clinical criteria Gene Alteration Mutation type Exon Reference
SM-01 39 Breast HBOC BRCA1 c.5203delTT Frameshift 18 BIC
SM-17 49/51 Ovarian/Breast HBOC BRCA1 c.3376 T > G; p.L1086X Nonsense 11 BIC
SM-25 69 Breast HBOC BRCA1 c.120A > G; p.M1V Missense 2 BIC
SM-69 33 Breast HBOC BRCA1 c.5242C > A; p.A1708E Missense 18 BIC
SM-74 50 Hemangioblastoma HBOC BRCA1 c.2080delA Frameshift 11 BIC
MO-07 34 Breast HBOC BRCA1 c.5382insC Frameshift 20 BIC
MO-09 42 Breast HBOC BRCA1 c.5382insC Frameshift 20 BIC
MO-45 48 Breast HBOC BRCA1 c.5382insC Frameshift 20 BIC
MO-13 32/44 Breast/Skin HBOC BRCA1 c.4831del5 Frameshift 16 BIC
MO-26 37 Breast HBOC BRCA1 c.1499insA Frameshift 11 BIC
MO-31 38/63 Breast/Peritoneal HBOC BRCA1 c.5563G > A; p.W1815X Nonsense 23 BIC
MO-37 (-) Breast HBOC BRCA1 c.3759G > T; p.E1214X Nonsense 11 BIC
MO-38 42/44 Breast/Breast HBOC BRCA1 c.307 T > A; p.L63X Nonsense 5 BIC
SM-50 36/47 Breast/Breast HBOC BRCA1 c.4794 + 1G > A Splice site 15 BIC
SM-80 42/48 Breast/Ovarian HBOC BRCA1 c.1446 A > T; p.K443X Nonsense 11 Current study
SM-81 55 Fallopian Tube HBOC BRCA1 c.5582insT Frameshift 23 Current study
SM-89 40 Breast HBOC BRCA1 c.4406 C > A; p.Y1429X Nonsense 13 Current study
MO-15 43/56 Breast/Ovarian HBOC BRCA1 c.560 + 2 T > A Splice site 7 Carraro et al. [28]
M0-28 48 Breast HBOC BRCA1 Exon 24 amplification LGR 24 Current study
SM-03 36/36 Breast/Ovarian HBOC BRCA1 Exon 16–17 deletion LGR 16-17 BIC
SM-08 33 Breast HBOC BRCA2 c.6174delT Frameshift 11 BIC
SM-46 32 Breast HBOC BRCA2 c.9709 A > T; p.K3161X Nonsense 25 BIC
SM-61 51 Breast HBOC BRCA2 c.9709A > T; p.K3161X Nonsense 25 BIC
SM-104 32 Breast HBOC BRCA2 c.3034del4 Frameshift 11 BIC
MO-02 53/63 Breast/Breast HBOC BRCA2 c.9610C > T, p.R3128X Nonsense 25 BIC
SM-53 30/49 Breast/Thyroid HBOC BRCA2 c.6242del4 Frameshift 11 Current study
SM-84 35 Breast HBOC BRCA2 c.8423 T > G; p.L2732X Nonsense 18 Current study
MO-41 47 Breast HBOC CHEK2 c.1100delC; p.Thr367MetfsX15 Frameshift 10 BIC
SM-31 49 Breast HBOC TP53 c.1010G > A; p.R337H Missense 10 IARC TP53
SM-31 49 Breast HBOC TP53 c.1010G > A; p.R337H Missense 10 IARC TP53
SM-82 29 Breast HBOC TP53 c.1010G > A; p.R337H Missense 10 IARC TP53
(-) Not available; LGR: Large Genomic Rearrangement; BIC: Breast cancer information core database; IARC TP53: IARC TP53 database.
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Figure 1 Characterization of a novel BRCA1 splice site variant (c.560 + 2 T > A) in one HBOC patient. A: Sequencing pattern of BRCA1
exon 7 from blood cell genomic DNA showing the c.560 + 2 T > A mutation. B: Agarose gel showing RT-PCR products obtained from the cDNA
of a tumor from patient MO-15 and one control sample (sporadic tumor negative for the c.560 + 2 T > A) using a forward primer in exon 6 and
a reverse primer in exon 8 of BRCA1. An additional 186-bp cDNA fragment caused by the partial deletion of exon 7 was observed in the tumor
sample of patient MO-15. C: Above, partial sequence of the expected fragment (258 bp) in the control tumor sample showing the exon 7–8
junction; below, partial sequence of the patient tumor cDNA showing the creation of a novel cryptic splice donor site causing the deletion of the
last 62 bp of BRCA1 exon 7 in the aberrant transcript. D: Schematic representation of the premature stop codon (p.Ser127Thrfs*11) created in
the BRCA1 mRNA after the frameshift deletion of the last 62 bp of exon 7 caused by the germ line splice site variant c.560 + 2 T > A. E: Amino
acid sequence of the expected truncated protein (137 aa) showing the alteration of 10 amino acids (in red) and creation of a premature stop
codon (*).
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criterion for Ashkenazi Jewish ancestry (criterion 7)
harbored pathogenic mutations, and patients fulfilling
criterion 6 showed a detection rate of 44% (4/9). Patients
younger than 45 yo without a family history of cancer
(criterion 1) did not present pathogenic mutations in our
cohort (Table 3).
Array CGH and gene dosage qPCR
Among the 120 cancer patients included in this study,
100 had array CGH data available from a previous study
[19], which were used for detecting CNVs within the 14
breast cancer susceptibility genes. After a careful visual
inspection, two of them were found to harbor CNVs in
Table 2 Variants of uncertain significance (VUSs)
Variant No. of families
carrying VUS
Co-occurrence with
pathogenic mutation
Gene BIC In silico analysis IARC-LOVD
databasePolyphen-2 SIFT Align GVGD
p.I1237M 1 No BRCA1 Unknown Benign Tolerated C0 -
p.S1448G 1 No BRCA1 Unknown Benign Affect C0 -
p.A1615T 1 No BRCA1 Unknown Possibly Affect C0 -
p.M1783T 1 No BRCA1 Unknown Probably Affect C55 -
p.K322Q 1 No BRCA2 Unknown Benign Affect C0 -
p.L366V 1 No BRCA2 Novel Benign Tolerated C0 -
p.A495T 1 No BRCA2 Novel Benign Tolerated C0 -
p.M784V 4 No BRCA2 Unknown Benign Tolerated C0 Class 3
p.K1533N 1 No BRCA2 Unknown Benign Tolerated C0 -
p.H1561N 1 Yes BRCA2 Unknown Benign Tolerated C0 -
p.M1915T 3 No BRCA2 Unknown Benign Tolerated C0 -
p.G2044V 1 Yes BRCA2 Unknown Benign Tolerated C0 -
p.V2138F 2 Yes BRCA2 Unknown Benign Tolerated C0 -
p.I2490T 3 Yes BRCA2 Unknown Benign Tolerated C45 -
p.I2944F 2 Yes BRCA2 Unknown Probably Affect C0 -
p.A3029T 1 No BRCA2 Unknown Benign Tolerated C0 -
p.I3412V 1 Yes BRCA2 Unknown Benign Tolerated C0
Align GVGD: C0 (Less likely to interfere in protein function), C15, C25, C35, C45, C55, C65 (More likely to interfere in protein function); Polyphen: Variant Benign,
Possibly damaging and Probably damaging; SIFT: Variant Tolerated (benign) or Affect protein function. LOVD-IARC: class 1 (Not pathogenic or of no clinical
significance), class 2 (Likely not pathogenic or of little clinical), class 3 (Uncertain), class 4 (Likely pathogenic), class 5 (definitely pathogenic).
Figure 2 Schematic representations of BRCA1/2 proteins. BRCA1/2 proteins with their functional domains and the localization of all identified
pathogenic mutations (red labels) and VUSs (black labels). Novel alterations are marked with an asterisk. The frequency of each alteration is represented by
gray dots. The red and green bars represent the detected genomic rearrangements. The black bar represents the ATM, CDH1 and RAD50 binding domain.
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PTEN and ATM genes. The exon-4 heterozygous
deletion in the ATM gene (Patient SM-46, carrier of a
pathogenic BRCA2 mutation, c.K3161*) and exon-2 het-
erozygous deletion in the PTEN gene (Patient SM-62)
were confirmed using the duplex qPCR gene dosage
method (Figure 4). However, both the array CGH probe
and gene dosage PCR primers for the PTEN gene were
located in the deleted region that has recently been
described as a polymorphic chromosomal deletion [21].
Discussion
In Brazil, data concerning the prevalence of BRCA1/2
mutations are limited. Previous studies using different
selection criteria have reported mutation frequencies
ranging from 2.3% to 20% [22-28]. The largest study
conducted in Brazil used the protein truncation test
(PTT) to evaluate 612 BC cases with high and medium
risks of breast cancer and found a mutation carrier
prevalence of 3.4% [25]. In the current study, we de-
tected a germ line mutation prevalence of 26% within
the BRCA1/2 genes, TP53 R337H and CHEK2 1100delC
in 120 Brazilian patients with clinical criteria for HBOC
(16.5% in BRCA1, 6% in BRCA2, 2.5% in TP53 and 1%
in CHEK2). Previous studies have described a mutation
detection rate ranging from 8.9 to 43.8% [29-31] in
BRCA1/2, revealing differences between our cohort and
others. Thus, it is important to note that our study was
based on an institutional registry and probably does not
represent the broad ethnic and socio-economic diversity
of the Brazilian population. This can partially explain
some inconsistency between different Brazilian studies,
in addition to the different screening methods and inclu-
sion criteria for selecting patients.
Regardless of specific populations and ethnic groups,
recurrent BRCA1/2 mutations are rarely detected in
hereditary breast cancer. In this sense, a wide range of
pathogenic mutations was detected in this series, which
is expected for an unrelated cohort of an ethnically mixed
population such as that of Brazil. The most frequent muta-
tion identified in this series was the Ashkenazi Jewish
5382insC variant, which was found in approximately 10%
of the mutation carriers. This is one of the most common
BRCA1 mutations identified worldwide and is found
both among Ashkenazi Jews and women of Slavic ori-
gin [32,33].
Splice-site mutations in the BRCA1 gene are considered
to be rare, and thus far, only a few splice-site mutations
have been reported in the BIC database. Using trans-
criptional analysis of the BC tumor harboring the novel
mutation c.560 + 2 T > A, we confirmed the presence of
an aberrant transcript that was not found in the control
sample. Interestingly, this variant was also reported in
another series of unrelated young Brazilian patients with a
positive family history recently reported by us [28].
Although we were able to show that the mutant allele can
Figure 3 BRCA1/2 mutation frequency. Mutation frequency
according to age of cancer onset.
Table 3 Mutation detection rate according to inclusion criteria
Hereditary Breast and Ovarian Cancer (HBOC) Distribution by criterion Number of mutation carriers Positive detection rate
1. BC ≤ 45 years of age (no family history) 11 0 0%
2. BC ≤ 45 years of age with ≥ 1 relative with BC, OC,
FTC and PPC at any age
42 14 33%
3. BC < 45 ≤ 50 years of age with ≥ 1 relative with
BC, OC, FTC and PPC ≤ 50 years of age
16 2 12%
4. BC >50 years of age with ≥ 1 relatives with
BC, OC, FTC and PPC at any age
28 5 18%
5. Two BC when the first occurrence was prior to age 50 5 1 20%
6. BC at any age plus OC, FTC and PPC at any age 9 4 44%
7. Ashkenazi Jewish ancestry 5 4 80%
8. OC, FTC and PPC at any age 3 1 33%
9. Male BC 1 0 0%
BC: Breast cancer; OC: ovarian cancer; FTC: Fallopian tube cancer; PPC: Primary peritoneal cancer.
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produce the aberrant transcript but not able to demon-
strate whether the mutant allele was still able to produce
the full-length BRCA1 transcript, this splice site was
considered pathogenic because it has been reported that
mutations in the highly conserved acceptor or donor sites
are pathogenic per se [34].
One of the main issues in the molecular diagnosis of
BRCA1/2 mutations is the effect of VUSs in protein
function. Several approaches have been used to determine
the pathogenicity of VUSs, including the investigation of
co-segregation within pedigrees, frequency in healthy con-
trols, lack of co-occurrence with pathogenic mutations,
and in silico analysis such as amino acid conservation and
the severity of amino acid change [35]. According to
the criteria adopted in this study, only the p.M784V
variant had an uncertain clinical relevance according
to the IARC-LOVD database; however, because of the
lack of co-segregation in one affected sister and the
presence of the variant in a set of 95 healthy indi-
viduals (data not shown), this variant is likely to have
little or no clinical relevance.
Our results demonstrated that the age at cancer diag-
nosis had a significant impact on the positive detection
rate. In this sense, we found that the group of early-
onset breast cancer patients (≤35 yo) is at a higher risk
of carrying pathogenic mutations in the BRCA1/2 genes
with a positive detection rate of 35%, which reached 42%
in cases with a family history of breast cancer (not shown).
In a previous study by our group, patients ≤ 35 years of
age showed a mutation rate of 20% in BRCA1/2 genes
with a significant increase of the detection rate in young
women with a positive family history (37.5%) [28]. The
concordance among these studies in early-onset breast
cancer patients strengthens the hypothesis that young
Brazilian women with a positive family history are at high
risk of being BRCA1/2 carriers.
Li-Fraumeni syndrome is inherited in an autosomal
dominant manner and is associated with germ line
mutations in the TP53 gene. Despite the broad range of
pathogenic mutations in this gene, a specific mutation
occurring in the tetramerization domain of the TP53
gene (p.R337H) has been reported at a high prevalence
Figure 4 Array CGH and Duplex qPCR. Validation of three selected DNA copy number alterations detected using array CGH in HBOC patients.
A: Chromosome 11 array CGH profile (lower panel) of a cancer patient (SM-46); the vertical blue bar indicates the affected genomic region, which
is enlarged in the upper panel showing a deletion in ATM exon 4 (upper panel). B: Duplex qPCR for the ATM exon 4 and a reference gene; the
ratio between the patient and control peaks of the melting curve was 0.63, which confirmed a one-copy deletion. C: Chromosome 10 array CGH
profile (lower panel) of a cancer patient (SM-62) showing a deletion in PTEN exon 2 (upper panel); the blue vertical bar in the chromosome
indicates the gene region, which is enlarged in the upper panel. D: Duplex qPCR for the PTEN exon 2 and reference gene; the ratio between the
patient and control peaks of the melting curve was 0.64, confirming the one-copy deletion. Coordinates of the enlarged gene region are given
according to the UCSC Feb. 2009 (GRCh37-Hg19) assembly.
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in southern and southeastern Brazil. Recent studies have
identified p.R377H carriers in a variety of tumors, in
particular, early breast cancer [36]. In our analysis, the
three carriers had breast cancer prior to the age of 50
without a family history of other tumors typical of Li-
Fraumeni syndrome. Therefore, due to the high preva-
lence of the R337H mutation in southeast Brazil, we
asserted that a genetic test for this variant is strongly
recommended for families matching clinical criteria for
HBOC and in whom mutation testing for BRCA1 and
BRCA2 is negative.
Germ line DNA CNVs have recently been implicated
in predisposition to different tumors [17]. In this regard,
Rouleau and colleagues [37] used an in-house array CGH
platform to search for copy number imbalances in ten
genes involved in hereditary breast and ovarian cancer
including BRCA1, BRCA2, CHEK2, BARD1, ATM,
RAD50, RAD51, BRIP1, RAP80 and PALB2. In a series of
472 patients, they found only three large rearrangements
in BRCA1/2, two in CHEK2 and one intronic deletion in
BRIP1. In our series, with the exception of RAP80, all
genes were also evaluated for DNA copy number imbal-
ances. We detected four large rearrangements (3% of the
cohort), thus confirming the two rearrangements affecting
BRCA1 and revealing two one-exon deletions in the ATM
and PTEN genes. Since we cannot rule out the presence of
point mutations in these 14 genes, we can only suggest
that germ line CNVs in these genes are at low frequencies.
Additionally, CNVs in both BRCA1 and BRCA2 genes
were also confirmed to be at low frequency in this
Brazilian HBOC series.
Germ line point mutations in ATM and PTEN have
been reported to play a role in breast cancer predispos-
ition [38-40]. However, to our knowledge, CNVs within
these genes had never been reported in HBOC patients.
In the current study, patient SM-46, who was found to
carry an exon 4 deletion in the ATM gene, also had a
pathogenic mutation in the BRCA2 gene; therefore, the
involvement of the ATM intragenic deletion with breast
cancer predisposition in this particular case remains to
be clarified.
Germ line mutations in the PTEN gene are associated
with the PTEN hamartoma tumor syndrome (PHTS) in
which Cowden syndrome (CS) is the most common
phenotype. Patients with CS are at an increased risk of a
variety of tumors including a 50% increased lifetime risk
for breast cancer [41]. Although one of our BC patients
presented a PTEN exon 2 deletion, recently, Sandell and
colleagues described an 899-bp intronic deletion located
58 bp upstream PTEN exon 2 (c.80-956_-58del899),
which was identified in 4% of British PHTS patients and
in 3% of healthy individuals [20]. Apparently, this British
alteration is the same found in our BC patient; one of
the primer pairs designed for duplex PCR was located
within this polymorphic region. Nevertheless, according
to Sandell and colleagues, the presence of this poly-
morphism in healthy individuals, the lack of aberrant
splicing and the co-occurrence with known pathogenic
mutations indicate that this variant is probably a poly-
morphism and has no phenotypic effect.
Conclusions
In summary, this is the most comprehensive BRCA1/2
mutation screening study of Brazilian BC patients from
families with hereditary breast and ovarian cancer. The
study demonstrates a high prevalence of BRCA1 point
mutations and low frequency of CNVs within the BRCA1
and BRCA2 genes. Moreover, the detection of the TP53
R337H variant in our series and the fact that this variant
has a founder effect in our population prompted us to
suggest that all female breast cancer patients with clinical
criteria for HBOC and negative for BRCA1/2 genes should
be tested for this variant. Additionally, the identifica-
tion of CNVs in other breast cancer susceptibility
genes revealed the complex genetic basis of this series
of 120 unrelated Brazilian women with hereditary breast
and ovarian cancer.
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